Abstract Library

#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)

Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Partelli S

Authors: Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L,

Keywords: small neuroendocrine pancreatic tumors, surveillance, surgery, follow-up,

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#2772 Vitamin Supplementation and a Personalized Diet in Patients with Neuroendocrine Tumors: The DIVIT Study

Introduction: Patients with neuroendocrine tumors (NETs) are at risk for vitamin deficiencies and poor nutritional status due to excessive serotonin production, diarrhea, previous gastrointestinal surgery, and/or treatment with somatostatin analogues (SSA). Little knowledge exists about vitamin deficiency and how patients should be supported for the deficiencies they develop during their long-lasting disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Stelwagen J

Authors: Stelwagen J, de Hosson L, Sijtema B, van Faassen M, Kema I,

Keywords: Vitamins, nutritional support, supplementation, vitamin deficiency, single-arm intervention,

#2713 The Economic Impact to Patients with Neuroendocrine Tumours

Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Wyld D

Authors: Wyld D, Elliott T, Wakelin K, Leyden S, Leyden J,

Keywords: Financial Toxicity, Economic impact, Quality of Life, NETs,